| Cat.No. | Name | Information |
|---|---|---|
| M13528 | AZD-5991 | AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay. |
| M13526 | A-1155463 | A-1155463 is a highly potent and selective BCL-XL inhibitor with an EC50 of 70 nM in Molt-4 cell. |
| M5273 | S63845 | S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM. |
| M5226 | UMI-77 | UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family. |
| M4385 | Gossypol | Gossypol has been known to exert a potential for anti-cancer, anti-inflammatory and other important therapeutic activities, gossypol binds and antagonizes anti-apoptotic effect of Bcl-2 family proteins. |
| M2017 | ABT-199 | ABT-199 (Venetoclax) is a highly potent, orally bioavailable and BCL-2 inhibitor. ABT-199 is the first inhibitor targeting Bcl-2 and PPI. |
| M1637 | ABT-263 | ABT-263 (Navitoclax) is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x (L), and Bcl-w. |
| M45050 | Sonrotoclax | Sonrotoclax is an orally active, potent Bcl2 inhibitor.Sonrotoclax exhibits potent cell killing effects on a variety of lymphoma and leukemia cell lines. Sonrotoclax is effective in killing a variety of lymphoma and leukemia cell lines and may be used in studies related to hematologic tumors. |
| M29950 | BT2 | BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM. |
| M22479 | Lisaftoclax | Lisaftoclax (APG-2575) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. |
| M21643 | VU661013 | VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM to human MCL-1 in a TR-FRET assay. VU661013 destabilizes BIM/MCL1 association, leads to apoptosis in AML, and is active in venetoclax-resistant cells and xenografts. |
| M21156 | BI-3802 | BI-3802 is a potent degradation of oncogenic transcription factor BCL6 with strong inhibitory effect on target genes and anti-proliferative effect.BI-3802 inhibits the BTB structural domain of BCL6, corresponding to an IC50 value ≤ 3 nM.BI-3802 has anti-tumor activity. |
| M20819 | Obatoclax (GX15-070) | Obatoclax (GX15-070) is an antagonist of Bcl-2 with an Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. |
| M13529 | BAI1 | BAI1 is a selective and allosteric inhibitor of BAX, an apoptosis regulator. BAI1 directly binds to BAX and allosterically inhibits BAX activation. BAI1 has the potential for the research of diseases mediated by BAX-dependent cell death. |
| M13527 | (R)-(-)-Gossypol acetic acid | (R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. |
| M13381 | Pyridoclax | Pyridoclax is a potential McL-1 inhibitor. |
| M13380 | Tapotoclax | Tapotoclax is an inhibitor of myeloid leukemia cell differentiation protein McL-1 (myeloid leukemia-1) with a Ki value of 0.13 nM and has potential pro-apoptotic and anti-tumor activity. |
| M10283 | AZD-5991 Racemate | AZD-5991 Racemate is a Mcl-1 inhibitor with an IC50 of <3 nM in FRET assay. |
| M9419 | Bax inhibitor peptide V5 | Bax inhibitor peptide V5 is a Bax-mediated apoptosis inhibitor. |
| M9248 | CID5721353 | CID5721353 is a B-Cell Lymphoma 6 inhibitor with IC50 of 212 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
